Aptargroup, Inc. ATR
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 7, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
7 paragraphs in Risk Factors of the 10-K filed Feb 6, 2026 with nothing like them in the 10-K filed Feb 7, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
The rapid evolution and increased adoption of artificial intelligence technologies may intensify our cybersecurity risks. In addition, as locally hosted information technology environments and data centers continue to decline or are decommissioned,we may increasingly rely on cloud-based solutions to host applications and data. Any disruption, failure or security incident affecting our internal systems or our third-party or cloud-based service providers could result in the inability to host or access applications, loss of critical or confidential information, or interruptions to our operations.
A material failure or disruption at one or more of our manufacturing facilities could adversely affect our ability to generate sales and meet customer demand. Our ability to generate sales and meet customer demand depends on the continued operation of our manufacturing facilities, many of which involve complex, specialized, and highly regulated manufacturing environments, including clean-room operations. A material failure or disruption at one or more of these facilities could occur for a variety of reasons, including significant equipment or mechanical failures, information technology or systems outages, cybersecurity incidents, power interruptions, fires, explosions, natural disasters, extreme weather events, labor disruptions, public health events, or other causes beyond our control.
If operations at any of our manufacturing facilities were materially disrupted, our ability to produce and deliver products to customers could be adversely affected for a period of time. Interruptions in manufacturing could result in lost sales, delayed customer deliveries or product launches, and damage to customer relationships. Manufacturing disruptions could also increase our costs due to production inefficiencies, inventory losses or write-offs, expedited shipping, or the need to transfer production to other facilities or rely on third-party manufacturers, which may be subject to capacity constraints, regulatory requirements, or higher costs.
Certain of our products, components, tools, machines, or molds are manufactured at a limited number of facilities or rely on specialized equipment or processes, which may not be easily or quickly replaced. In addition, in the pharmaceutical industry, manufacturing disruptions may be particularly difficult to remediate due to regulatory requirements, validation processes, and customer qualification timelines, which could extend the duration and impact of any disruption.
Any of these events could materially adversely affect our business, financial condition, results of operations, cash flows, and reputation.
We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the ordinary course of our business, which include intellectual property infringement, product liability, commercial, employment, tort, business interruption and other litigation. For example, in May 2025, Nemera filed patent infringement actions against us in France and Germany relating to certain of our ophthalmic products. In October 2025, an EPO hearing invalidated Nemera’s main patent claim while allowing an amended claim to continue. In addition, in September 2025, ARS Pharmaceuticals Operations, Inc. filed an antitrust lawsuit against us in the United States District Court for the Southern District of California, alleging violations of U.S. competition laws related to supply of certain components and are seeking injunctive relief and damages. Refer to Note 13 – Commitments and Contingencies of the Notes to the Consolidated Financial Statements for additional information regarding these actions
We are also from time to time subject to claims from third parties suggesting that we may be infringing on their intellectual property rights. For example, in May 2025, Nemera filed patent infringement actions against us in France and Germany relating to certain of our ophthalmic products. In October 2025, an EPO hearing invalidated Nemera’s main patent claim while allowing an amended claim to continue. Refer to Note 13 – Commitments and Contingencies of the Notes to the Consolidated Financial Statements for additional information.
Paragraphs in the 10-Q filed Oct 30, 2026 that were not in the one before
New in the latest 10-Q
21 paragraphs in the 10-Q filed Oct 30, 2026 with nothing like them in the 10-Q filed Jul 31, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
In thousands, brackets denote cash outflows Nine Months Ended September 30, 2026 2025 Cash Flows from Operating Activities: Net income $ 193,599 $ 318,227 Adjustments to reconcile net income to net cash provided by operations: Depreciation 198,044 177,412 Amortization 32,866 33,373 Stock-based compensation 33,043 36,772 Provision for CECL 4,374 516 Loss (gain) on disposition of fixed assets 484 77 Loss on Russia deconsolidation 58,020 — Net loss (gain) on remeasurement of equity securities 1,160 (845) Deferred income taxes (5,257) (31,851) Defined benefit plan expense 6,898 10,232 Equity in results of affiliates (3,224) (6,142) Gain on remeasurement of equity method investment — (26,518) Impairment loss 5,007 — Changes in balance sheet items, excluding effects from foreign currency adjustments: Accounts and other receivables (101,728) (66,812) Inventories (56,698) (22,782) Prepaid and other current assets (17,906) (28,064) Accounts payable, accrued and other liabilities 60,132 6,950 Income taxes payable (5,250) (1,281) Retirement and deferred compensation plan liabilities (6,183) (5,891) Retirement and deferred compensation plan assets 420 (7,314) Other changes, net (8,023) 247 Net Cash Provided by Operations 389,778 386,306 Cash Flows from Investing Activities: Capital expenditures (191,965) (183,600) Proceeds from government grants — 3,308 Proceeds from sale of property, plant and equipment 1,544 2,103 (Purchases) and maturities of short-term investments, net (1,462) 2,813 Acquisition of businesses, net of cash acquired and release of escrow (156) (28,221) Acquisition of intangible assets, net (1,933) (4,301) Investment in equity securities — (7,258) Cash balance of deconsolidated subsidiary (29,977) — Notes receivable, net 1,355 37 Net Cash Used by Investing Activities (222,594) (215,119)
Read in the 10-Q
In thousands, brackets denote cash outflows Nine Months Ended September 30, 2026 2025 Cash Flows from Financing Activities: Proceeds from notes payable and overdrafts 20,826 2,105 Repayments of notes payable and overdrafts (21,281) (1,946) Proceeds of short-term revolving credit facility, net 50,000 144,620 Proceeds from long-term obligations 6,112 1,204 Repayments of long-term obligations (160,897) (36,490) Payment of contingent consideration obligation (3,730) — Dividends paid (92,054) (89,287) Proceeds from stock option exercises 22,420 14,869 Purchase of treasury stock (179,973) (190,005) Redeemable noncontrolling interest 1,106 703 Net Cash Used by Financing Activities (357,471) (154,227) Effect of Exchange Rate Changes on Cash (7,961) 16,253 Net Decrease in Cash and Equivalents and Restricted Cash (198,248) 33,213 Cash and Equivalents and Restricted Cash at Beginning of Period 404,849 223,844 Cash and Equivalents and Restricted Cash at End of Period $ 206,601 $ 257,057
Read in the 10-Q
For all periods presented through September 21, 2026, the operating results of our Russian subsidiary are included in our consolidated financial statements. As of September 21, 2026, we deconsolidated our Russia operations from our consolidated financial statements and recognized a loss on deconsolidation. See Note 20 - Deconsolidation for more information.
Read in the 10-Q
The effective tax rate for the nine months ended September 30, 2026 and 2025, was 28.1 % and 20.4 % respectively. The effective tax rate for the nine months ended September 30, 2026 reflects a negative 5.8 % tax impact from the loss on deconsolidation of our Russian subsidiary on September 21, 2026. The effective tax rate for the nine months ended September 30, 2025 reflects deferred tax benefits from valuation allowance releases ( 3.1 %), and a benefit related to the gain from remeasurement of an equity investment upon consolidation ( 1.6 %).
Read in the 10-Q
(1) The rate represents the weighted-average interest rate as of September 30, 2026.
Read in the 10-Q
Show the other 16
(1) The rate represents the weighted-average interest rate as of September 30, 2026.
Read in the 10-Q
Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2024 $ (426,049) $ 5,522 $ (8,948) $ (429,475) Other comprehensive income (loss) before reclassifications 237,788 344 (16,590) 221,542 Amounts reclassified from accumulated other comprehensive income — 438 — 438 Net current-period other comprehensive income (loss) 237,788 782 (16,590) 221,980 Balance - September 30, 2025 $ (188,261) $ 6,304 $ (25,538) $ (207,495) Balance - December 31, 2025 $ (179,891) $ 18,078 $ (24,569) $ (186,382) Other comprehensive (loss) income before reclassifications (50,191) 3,505 8,490 (38,196) Amounts reclassified from accumulated other comprehensive income — 259 — 259 Reclassification to earnings related to Russia deconsolidation 18,658 — — 18,658 Net current-period other comprehensive (loss) income (31,533) 3,764 8,490 (19,279) Balance - September 30, 2026 $ (211,424) $ 21,842 $ (16,079) $ (205,661)
Read in the 10-Q
At this stage, each of the above matters is too preliminary to form a judgment as to whether an adverse outcome is probable, and we are unable to estimate the possible loss or range of loss, if any.
Read in the 10-Q
(5) Russia deconsolidation impact represents $ 58.0 million loss on Russia deconsolidation on the Condensed Consolidated Statements of Income, $ 2.6 million for CECL reserves placed on uncollectible accounts, and $ 0.5 million for legal fees recorded in selling, research & development and administrative on the Condensed Consolidated Statements of Income.
Read in the 10-Q
(6) The gain from remeasurement of equity method investment represents the remeasurement of our previously held minority equity interest in BTY at fair value.
Read in the 10-Q
Effective as of September 21, 2026, we concluded that we no longer met the accounting criteria for consolidation of our Russian subsidiary due to a loss of control over our Russian operations. On September 21, 2026, the President of the Russian Federation issued a governmental decree that placed the Company's Russian subsidiary, OOO Aptar Vladimir ("Aptar Vladimir"), under external administration. Historically all three segments produced and sold products out of our Russian subsidiary. As part of our segment realignment, this subsidiary was primarily used by our Closures segment.
Read in the 10-Q
As of the close of the third quarter 2026, we deconsolidated and changed to the cost method of accounting for our Russian operations. We recorded a $ 58.0 million loss on deconsolidation as we reduced the value of our cost method investment in the Russian subsidiary resulting in the full impairment of that investment. We also recorded a $ 2.6 million CECL reserve related to all Russian receivables held by our other subsidiaries and $ 0.5 million in legal costs. The recorded loss on deconsolidation also included $ 18.7 million of historical cumulative translation adjustments related to our Russian operations that had previously been recorded in accumulated other comprehensive income within equity. Additionally, $ 30.0 million of cash held by our Russian subsidiary to which we no longer have access is reflected within the investing section of the Condensed Consolidated Statements of Cash Flows.
Read in the 10-Q
We have determined the fair value of our investment in our Russian subsidiary to be insignificant because recovery of any amounts from the Russian government related to the expropriation is highly unlikely given uncertainty around any potential recovery through legal proceedings. Russian counter-sanction measures restrict the Company’s ability to sell, transfer or repatriate value from the Russian business and that any disposition would require Russian governmental approval, and we have no continuing commercial relationship with, or obligations to, Aptar Vladimir.
Read in the 10-Q
As of September 21, 2026, we no longer include sales, earnings or net assets of our Russian subsidiary within our consolidated financial statements. Under the cost method of accounting, we will recognize earnings only to the extent cash is received from our Russian subsidiary. We will monitor the extent of our ability to control our Russian operations as our current situation in Russia may change over time and lead to re-consolidation at a future date. Aptar will account for any potential recovery from the Russian government, the external administrator or a sale only when realized.
Read in the 10-Q
For all periods presented through September 21, 2026, the operating results of our Russian subsidiary are included in our consolidated financial statements. As of September 21, 2026, we deconsolidated our Russia operations from our consolidated financial statements and recognized a loss on deconsolidation. See Note 20 - Deconsolidation for more information.
Read in the 10-Q
Net other income decreased $89.6 million to $58.9 million of expense in the third quarter of 2026 from $30.7 million of income in the same period of the prior year. As discussed in Note 20 - Deconsolidation to our Condensed Consolidated Financial Statements, during the third quarter of 2026 we deconsolidated our Russian operations and recorded a $58.0 million loss on deconsolidation. We also recorded approximately $3.5 million of impairment losses in the third quarter of 2026 and realized an unfavorable foreign currency impact of $1.5 million which was offset by a pension curtailment gain of approximately $3.3 million. During the third quarter of 2025, we realized a $26.5 million remeasurement gain related to our additional investment in BTY.
Read in the 10-Q
The effective tax rate for the nine months ended September 30, 2026 and 2025, was 28.1% and 20.4% respectively. The effective tax rate for the nine months ended September 30,2026 reflects a negative 5.8% tax impact from the loss on deconsolidation of our Russian subsidiary on September 21, 2026. The effective tax rate for the nine months ended September 30, 2025 reflects deferred tax benefits from valuation allowance releases (3.1%), and a benefit related to the gain from remeasurement of an equity investment upon consolidation (1.6%).
Read in the 10-Q
Nine Months Ended September 30, 2026 Food Beverage Personal Care Other (2) Total
Read in the 10-Q
(1) Russia deconsolidation impact represents $58.0 million loss on Russia deconsolidation on the Condensed Consolidated Statements of Income, $2.6 million for CECL reserves placed on uncollectible accounts, and $0.5 million for legal fees recorded in selling, research & development and administrative on the Condensed Consolidated Statements of Income.
Read in the 10-Q
Item 6
Exhibit 10.1* ** Amendment Number Two to AptarGroup, Inc. Supplemental Retirement Plan.
Read in the 10-Q
Exhibit 10.2* ** Amended and Restated AptarGroup, Inc. Deferred Compensation Plan.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Oct 30, 2026 against Item 1A of the 10-K filed Feb 6, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
This 10-Q has no Item 1A (Risk Factors) text of its own, so there is nothing to compare. Many companies leave it out when their risks have not changed.
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 6, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 7, 2025
Where each one is used
- ars pharmaceuticals: We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the...
- generate sales: A material failure or disruption at one or more of our manufacturing facilities could adversely affect our ability to generate sales and meet customer demand. Our ability to generate sales and meet customer demand depends on the continued operation of our manufacturing facilities, many of which involve complex,...
- manufacturing disruptions: If operations at any of our manufacturing facilities were materially disrupted, our ability to produce and deliver products to customers could be adversely affected for a period of time. Interruptions in manufacturing could result in lost sales, delayed customer deliveries or product launches, and damage to...
- regulatory requirements: If operations at any of our manufacturing facilities were materially disrupted, our ability to produce and deliver products to customers could be adversely affected for a period of time. Interruptions in manufacturing could result in lost sales, delayed customer deliveries or product launches, and damage to...
- nemera filed: We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the...
- filed patent: We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the...
- patent infringement: We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the...
- infringement actions: We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
1 paragraph of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ATR/export.csv") into a cell.